Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group

Vertex Pharmaceuticals Inc and CRISPR Therapeutics AG's one-dose gene editing therapy for sickle cell disease would be cost effective if priced at up to $1.9 million, an influential U.S. drug pricing group said on Wednesday.